Alkaptonuria (AKU, MIM#203500), an iconic disease, has the distinction of being the disorder leading to the creation and evolution of the inherited metabolic disease branch of medicine (Garrod 1908) . Despite its distinctive status, and early recognition, progress in AKU has been gradual; there are still important gaps in our knowledge and understanding of the disease. Following the cloning of the AKU gene in 1996 (Fernandez-Canon et al 1996) , La Du posed the question BAre we ready to try to cure alkaptonuria?^(La Du 1998) . That era in which many of the genes mutated in Mendelian diseases were first identified and cloned, was a time of hope that there would be rapid progress in curing genetic disorders. In fact La Du went on to say BAttempts to treat alkaptonuria by use of genetic engineering to replace the missing enzyme no doubt will be made soon^. This optimism has been tempered by the many obstacles still to be overcome in developing safe and effective gene therapies, however progress is ongoing and with the further development of seamless gene correction technologies La Du's forecast will eventually come to pass.
However, whilst we are awaiting a cure, research on AKU continues. Recent progress has brought us to the stage of posing another question BAre we near to an effective therapy for Alkaptonuria?
A series of publications reported in this issue of the JIMD addresses some of these gaps in our knowledge of AKU. It is notable that three of these papers are focussed on the potential of nitisinone in treating the disease. Nitisinone, a phyodroxyphenyl pyruvate dioxygenase inhibitor, is not approved for AKU, although it has been used in a lifethreatening disease hereditary tyrosinaemia type 1 for more than 20 years with great success. Despite the inconclusive results of the first trials of nitisinone in AKU (Introne et al 2011) , the drug has been shown to be completely effective in inhibiting ochronosis in AKU mice (Preston et al 2014) and at lowering circulating HGA in AKU patients . The opportunity to modulate the tyrosine pathway by employing nitisinone brings with it considerations of the most appropriate time of life to begin treatment, both to minimise cost and to prevent unnecessary exposure to risk of toxicity. Keenan et al (2015) in this volume describe the experience of using nitisinone in a mouse analogue of the human disease, a much easier proposition to determine lifetime exposure to nitisinone, and show that nitisinone arrests but does not reverse ochronosis. This will be critical to help determine the most desirable time of life to begin taking nitisinone. Olsson et al (2015) describe the changes in tyrosine metabolism following nitisinone in a short-term study in AKU patients; clear efficacy has been demonstrated and in this short study no safety concerns were noted. However, safety concerns are paramount because nitisinone introduces a metabolic block proximal to the defect in AKU. Understanding the metabolic picture post-nitisinone is therefore necessary as this can allow the most appropriate dose of the drug to be used in AKU. The dose of nitisinone in AKU, needed to decrease HGA significantly, is much lower than that used in HT-1. Gertsman and colleagues (Gertsman et al 2015) describe changes in metabolism of tyrosine post-nitisinone in a small group of AKU patients, enabling further discussion in the context of good quality data that already exists.
Also in this volume, Arnoux et al (2015) summarise the place of diet and allied treatments, and proposes a sequential treatment strategy starting from childhood in alkaptonuria. This is clearly a logical approach in a disease markedly influenced by protein intake although longterm compliance can be challenging. Antioxidant strategies are unproven in long-term human experience such as when ascorbic acid is used (Phornphutkul et al 2002) . In addition, safety of long-term anti-oxidant approaches has been questioned (Vivekananthan et al 2003) .
While there have been considerable advances in understanding the genetic aspects of AKU, there is a lack of systematic information, for example a clear demonstration of the kind of genetic defect prevalent in the UK. Usher and colleagues (Usher et al 2015) describe genetic data from a large cohort of UK patients, which could prove useful in definitive diagnosis and family screening by highlighting mutations frequent in the population that could be targeted for identification. At present, there is little data supporting a clear phenotype/genotype interaction.
Ochronosis is a process that targets the connective tissue especially cartilage, leading to serious musculoskeletal morbidity as the dominant clinical feature in AKU. While there are reliable assays to measure the metabolic abnormalities of AKU, nothing has been described to allow the detection of connective tissue damage. Genovese et al (2015) have for the first time shown that there are reliable biomarker changes in AKU that can inform on the stage of the disease and its progression. Hopefully long-term studies and further validation may show that these biomarkers may reflect modulation of the disease by HGA-lowering therapies. It is still not known when ochronosis begins or takes hold and studies of biomarkers may allow us to answer this question.
Systemic circulation carries elevated HGA throughout the body leading to its deposition in multiple tissues and organs; it is presumed that HGA by oxidative polymerisation via a benzoquinone intermediate is converted to a melanin-like pigment, a process termed ochronosis. The exact nature and genesis of the ochronotic pigment is still a matter of debate and Roberts et al have attempted to summarise this complex area in their manuscript (2015) .
Most published data suggest that significant expression of the HGD gene is only seen in the liver and kidney. Santucci and colleagues describe the presence of HGD in the brain, an organ which when examined at post-mortem showed no ochronosis . Furthermore, patients with AKU do not display central nervous system features in clinical assessment, except for the very rare descriptions of Parkinson's disease, which has been considered a coincidental association of a commoner disease with one that is ultrarare (Aquaron et al 1995) . Peripheral and spinal neural disease is often seen and is secondary to the musculoskeletal involvement in the disease (Kusakabe et al 1995; Koji et al 2008) . Millucci et al (2015) have also demonstrated amyloid by histological techniques, in vitro studies and some ex vivo testing. Amyloid has long been associated with chronic inflammatory states such as rheumatoid arthritis, and which could well include spondyloarthropathy of AKU. Redox processes are clearly involved in the metabolism of HGA and this manuscript describes local metabolic changes affecting inflammatory metabolism and immunity.
Ochronosis is the process by which a melanin-like pigment forms in connective tissue. This pigment alters the structural properties of the tissue leading to increased rigidity. Cartilage is highly susceptible to ochronosis, especially articular cartilage, leading to the severe devastating osteoarticular disease characterised by impaired human locomotion. Barton et al (2015) describe the changes in gait in AKU and help understand the evolution of disability in the condition.
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